Category: Patient-focused Drug Development

On April 6, the U.S. Food and Drug Administration held a public meeting on Patient-Focused Drug Development (PFDD) for sarcopenia. The focus of the meeting was to obtain patient perspectives on “symptoms and the daily impacts of their condition, current approaches to treatment, and decision factors taken into account when selecting a treatment.”

On April 4, the Alliance for Aging Research’s Vice President of Public Policy Cynthia Bens will testify before the U.S. Senate Committee on Health, Education, Labor and Pensions about the reauthorization of the Prescription Drug User Fee Act and the Medical Device User Fee Act. You can watch the hearing here.

In response to a call from the U.S. Food and Drug Administration (FDA) for feedback on its proposed Commitment Letter for the sixth reauthorization of the Prescription Drug User Fee Act (PDUFA), the Alliance for Aging Research submitted comments to the FDA for consideration.

The Alliance provided comments in response to the U.S. Food and Drug Administration's PDUFA VI Commitment Letter.

On April 7, the Alliance's Vice President of Public Policy Cynthia Bens will participate in a symposium titled "Frailty as a Baseline Stratification Parameter and Potential Therapeutic Target" at the 28th Annual EuroMeeting in Hamburg, Germany.

Participating in Alzheimer's disease clinical trials is a valuable way you and your loved ones can personally impact this disease.

We are sharing the following information about two new clinical studies.

Alliance Vice President of Public Policy Cynthia Bens took part in two important meetings at the U.S. Food and Drug Administration this week.

ACT-AD Coalition Hosts Its 7th Annual Meeting

Nonprofit Leader Dan Perry to Offer Insights at MipTec European Health Care Innovation Conference